1. Presented By Luca Malorni at 2017 ASCO Annual Meeting
A phase II trial of the CDK4/6 inhibitor Palbociclib (P) as single agent or in combination with the same endocrine therapy (ET) received prior to disease progression, in patients (pts) with hormone receptor positive (HR+) HER2 negative (HER2–) metastatic breast cancer (mBC) (TREnd trial)
Presented By Luca Malorni at 2017 ASCO Annual Meeting

2. Presented By Luca Malorni at 2017 ASCO Annual Meeting
Background
Presented By Luca Malorni at 2017 ASCO Annual Meeting

3. To Reverse Endocrine resistance (TREnd) trial: aims
Presented By Luca Malorni at 2017 ASCO Annual Meeting

4. Presented By Luca Malorni at 2017 ASCO Annual Meeting
TREnd study design
Presented By Luca Malorni at 2017 ASCO Annual Meeting

5. Study endpoints and statistical assumptions
Presented By Luca Malorni at 2017 ASCO Annual Meeting

6. Baseline pts characteristics
Presented By Luca Malorni at 2017 ASCO Annual Meeting

7. Prior treatment for mBC
Presented By Luca Malorni at 2017 ASCO Annual Meeting

8. Study treatment administration and dose intensity
Presented By Luca Malorni at 2017 ASCO Annual Meeting

9. Presented By Luca Malorni at 2017 ASCO Annual Meeting
Slide 9
Presented By Luca Malorni at 2017 ASCO Annual Meeting

10. Duration of Clinical Benefit
Presented By Luca Malorni at 2017 ASCO Annual Meeting

11. Progression free survival (PFS)
Presented By Luca Malorni at 2017 ASCO Annual Meeting

12. PFS by duration of prior ET
Presented By Luca Malorni at 2017 ASCO Annual Meeting

13. Selected adverse events
Presented By Luca Malorni at 2017 ASCO Annual Meeting

14. Presented By Luca Malorni at 2017 ASCO Annual Meeting
Conclusions
Presented By Luca Malorni at 2017 ASCO Annual Meeting

15. Presented By Luca Malorni at 2017 ASCO Annual Meeting
Acknowledgements
Presented By Luca Malorni at 2017 ASCO Annual Meeting